Skip to main content
PVLA
NASDAQ Life Sciences

Palvella Unveils Third QTORIN Program: Topical Docetaxel for EMPD

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$147
Mkt Cap
$2.143B
52W Low
$72.225
52W High
$179.95
52W Position info
104% above low
Off High info
18% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

PVLA has more than doubled off its 52-week low of $72.225.

Summary

Palvella announced QTORIN docetaxel, a third QTORIN platform candidate targeting Extramammary Paget's disease, with IND-enabling work underway and an FDA meeting planned for 1H 2027.


Key Events · Product Development and Regulatory · PVLA

  • Third QTORIN Program Announced

    QTORIN docetaxel targets Extramammary Paget's disease, a rare genital and perianal skin cancer with no FDA-approved therapy and an estimated more than 10,000 U.S. patients.

  • Early-Stage Development Timeline

    IND-enabling activities have been initiated; Palvella plans an FDA meeting in 1H 2027 and a Phase 2 study afterward under the 505(b)(2) pathway.

  • Evidence Base Is External

    The rationale rests on published real-world I.V. docetaxel data — 51.6% ORR in 93 patients, with 52.7% Grade 3+ neutropenia and 24.7% discontinuing for adverse events — not on Palvella's own clinical trial results.

  • No Capital Impact

    The 8-K is an Item 7.01/8.01 disclosure with a presentation and press release; no financing, share issuance, or change to the $236.7 million cash position reported for September 30.


Analysis · PVLA · Life Sciences

Palvella has added a third pipeline asset: QTORIN docetaxel for Extramammary Paget's disease, a rare genital and perianal skin cancer with no FDA-approved therapy and an estimated more than 10,000 U.S. patients. The program is early — IND-enabling work has started, an FDA meeting is planned for 1H 2027, and a Phase 2 study would follow — so it adds pipeline breadth and a new multi-billion-dollar TAM claim rather than near-term revenue. Supporting evidence comes from real-world I.V. docetaxel data (51.6% ORR in 93 patients), not from Palvella's own clinical results. Meanwhile, the lead asset, QTORIN rapamycin, is already under FDA Priority Review following the October 28 NDA acceptance. Investors get a broader platform story ahead of that review, but no new cash, no dilution, and no change to the near-term regulatory calendar.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PVLA was trading at $147.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $72.23 to $179.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PVLA - Latest Insights

PVLA
Nov 05, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $153.30
Real-time Price: $147.00 info
Change: -$6.30 (-4%) info
Market Cap: $2.143B info
PVLA
Nov 05, 2026, 7:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $153.30
Real-time Price: $147.00 info
Change: -$6.30 (-4%) info
Market Cap: $2.143B info
PVLA
Oct 28, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $127.00
Real-time Price: $147.00 info
Change: +$20.00 (+16%) info
Market Cap: $2.143B info
PVLA
Oct 28, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $134.99
Real-time Price: $147.00 info
Change: +$12.01 (+9%) info
Market Cap: $2.143B info
PVLA
Aug 31, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $150.34
Real-time Price: $147.00 info
Change: -$3.34 (-2%) info
Market Cap: $2.143B info